ALNY News and Press, Alnylam Pharmaceuticals Inc. From 05/04/23

2023-05-04 12:22:09 ET Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communication Yvonne Greenstreet – Chi...

2023-05-04 10:49:30 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) traded flat on Thursday after Citi upgraded the developer of RNA-targeted therapeutics to Neutral from Sell following the company's better-than-expected Q1 2023 results. Carlsbad, California-based biotech reported...

2023-05-04 08:04:24 ET Alnylam Pharmaceuticals press release ( NASDAQ: ALNY ): Q1 Non-GAAP EPS of -$1.06 beats by $0.37 . Revenue of $319.29M (+49.7% Y/Y) beats by $6.76M . Reiterated 2023 Financial Guidance, Including Combined Net Product Revenues of $1,200 Mi...

− Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth Compared to Q1 2022 – − Reported Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 1:40 pm PT (4:40 pm ET) at the Encore Hotel in Las Vegas. A l...

2023-05-03 13:37:29 ET Alnylam Pharmaceuticals ( NASDAQ: ALNY ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open. The consensus EPS Estimate is -$1.43 (+4.0% Y/Y) and the consensus Revenue Estimate is $312.53M (+46.5% Y/Y). Over the...

– Successfully Met Goals Outlined in MassBio’s Diversity, Equity, and Inclusion (DE&I) Industry Pledge – – New Disclosures of Company’s Impact on Planet—Including Multiyear Data on Scope 1, Scope 2, and Select Scope 3 Greenhouse Gas (GHG) ...

2023-04-26 17:15:43 ET For further details see: Partial clinical hold placed on Alnylam, Regeneron RNAi Alzheimer's candidate

– Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date – – Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing ...

- Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date - - Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing to Date - - R...